Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group.
Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX; International DCB Consensus Group.
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402. doi: 10.1016/j.jcin.2020.02.043. Epub 2020 May 27.
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
Erlinge D, Andersson J, Fröbert O, Törnerud M, Hamid M, Kellerth T, Grimfjärd P, Winnberg O, Jurga J, Wagner H, Zwackman S, Adielsson M, Alström P, Masoe E, Ulvenstam A, Millgård J, Böhm F, Held C, Renlund H, Oldgren J, Smits PC, Elek C, Abizaid A, James S.
Lancet. 2024 Nov 2;404(10464):1750-1759. doi: 10.1016/S0140-6736(24)02227-X. Epub 2024 Oct 28.
Comparison of the Effects of Indobufen and Aspirin in Older Patients with Coronary Artery Disease After Coronary Drug-Eluting Stent Implantation: A Prospective Randomized Single-Center Study.
Wu Y, Gao Z, Jin Q, Zheng J, Xu H, Tu X.
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241309633. doi: 10.1177/10760296241309633.
Clinical Utility of Intravascular Imaging: Past, Present, and Future.
Mintz GS, Matsumura M, Ali Z, Maehara A.
JACC Cardiovasc Imaging. 2022 Oct;15(10):1799-1820. doi: 10.1016/j.jcmg.2022.04.026. Epub 2022 Sep 14.
DynamX sirolimus-eluting Bioadaptor versus the zotarolimus-eluting Resolute Onyx stent in patients with de novo coronary artery lesions: Design and rationale of the multi-center, international, randomized BIODAPTOR-RCT.
Saito S, Nef HM, Webster M, Verheye S; DynamX RCT investigators.
Cardiovasc Revasc Med. 2023 Oct;55:76-82. doi: 10.1016/j.carrev.2023.05.010. Epub 2023 May 23.
Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation.
Hong SJ, Kim H, Ahn CM, Kim JS, Kim BK, Ko YG, Hong BK, Choi D, Jang Y, Hong MK.
Yonsei Med J. 2019 Sep;60(9):824-831. doi: 10.3349/ymj.2019.60.9.824.
Is coronary artery tortuosity a predisposing factor for drug-eluting stent restenosis?
Levent F, Senoz O, Emren SV, Emren ZY, Gediz RB.
Herz. 2022 Feb;47(1):73-78. doi: 10.1007/s00059-021-05036-z. Epub 2021 Apr 24.
Comparison of Coronary Artery Bypass Grafting and Drug-Eluting Stent Implantation in Patients With Chronic Kidney Disease: A Propensity Score Matching Study.
Li Y, Hou X, Liu T, Xu S, Huang Z, Xu X, Dong R.
Front Cardiovasc Med. 2022 Apr 1;9:802181. doi: 10.3389/fcvm.2022.802181. eCollection 2022.
Long-term clinical outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease.
Higami H, Shiomi H, Niki S, Tazaki J, Imai M, Saito N, Makiyama T, Shizuta S, Shioi T, Ono K, Kimura T.
Cardiovasc Interv Ther. 2015 Jul;30(3):189-97. doi: 10.1007/s12928-014-0297-x. Epub 2014 Sep 7.
Twelve months clinical outcomes of ultrathin strut sirolimus-eluting stent in real-world Indian patients with coronary artery disease.
Ajmera P, Pothineni R, Chawla KK, Mantravadi SS, Jariwala P, Vijan V, Vijan V.
Am J Cardiovasc Dis. 2022 Oct 15;12(5):262-271. eCollection 2022.
